While RT+L19–IL2 resulted in superior tumor response as compared with RT alone in both CT26 and C51 tumor models, which is in agreement with our previously published data,18 the therapeutic outcomes of RT+anti-CTLA-4 and RT+anti-PD-L1 as compared with RT were significantly better only in CT26 tumors. Here, CTLA4 is linked to neoplasm.